Faculty Information 2/15/2013
|
|
- Randell Leo Stokes
- 5 years ago
- Views:
Transcription
1 Timothy Reilly, PharmD, BCPS, CGP, FASCP Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Faculty Information Presenter: Timothy Reilly, PharmD, BCPS, CGP, FASCP Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey Piscataway, New Jersey Moderator: Elena Beyzarov, PharmD Director of Scientific Affairs Pharmacy Times Office of Continuing Professional Education Plainsboro, New Jersey Intended Audience: Pharmacists This activity is supported by an educational grant from Teva Pharmaceuticals, Ltd. 1
2 Disclosures and COI Resolution Timothy Reilly, PharmD, BCPS, CGP, FASCP, has disclosed faculty honoraria received from: New Jersey Society of Health-System Pharmacists, New Jersey Pharmacists Association, Trinitas Regional Medical Center. His spouse is an employee and stockholder for Johnson & Johnson. Pharmacy Times Office of Continuing Professional Education Planning Staff Judy V. Lum, MPA, Elena Beyzarov, PharmD, and Donna W. Fausak have no financial relationships with commercial interests to disclose. Pharmacy Times Office of Continuing Professional Education uses an anonymous peer review process to resolve all conflicts of interest (COI). The peer reviewers used for this activity have no relevant financial relationships with commercial interests to disclose. Disclaimer The contents of this webinar may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. The information provided in this CPE activity is for continuing medical and pharmacy education purposes only and does not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the faculty or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not based on approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources for all products discussed. The opinions expressed in the content and provided verbally by faculty in this Webinar are solely those of the individual faculty members and do not reflect those of Pharmacy Times Office of Continuing Professional Education or the company providing commercial support for this CPE activity. 2
3 Learning Objectives At the end of this presentation, the pharmacist will be able to: Describe the epidemiology and pathophysiology of Parkinson s Disease (PD) Evaluate the management of early-stage and advanced stage PD Discuss current and emerging pharmacologic therapy and explore therapeutic challenges Examine dose titration strategies and management of treatment-related adverse effects Explore the pharmacist s role in optimizing treatment benefits and enforcing treatment adherence Timothy Reilly, PharmD, BCPS, CGP, FASCP Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey tjreilly@pharmacy.rutgers.edu 3
4 Epidemiology Affects up to 1 million adults in the US Prevalence and incidence increases with age Usual age at diagnosis: 55 to 65 years Male predominance Chen JJ, et al. Chapter 68. Parkinson's Disease. In: Talbert RL et al, eds. Pharmacotherapy: A Pathophysiologic 4
5 Etiology Free radical production from dopamine degradation Aging Genetics Environmental factors Pesticides Heavy metals (eg, Fe, Mn) Rural living Well water Chen JJ et al. Chapter 68. Parkinson's Disease. In: Talbert RL et al, eds. Pharmacotherapy: A Pathophysiologic Pathophysiology Degeneration of dopamine (D)-producing neurons and presence of Lewey bodies in substantia nigra Initially in medulla oblongata, locus coeruleus, raphe nuclei, olfactory bulb Progresses to midbrain Possible implication of N-methyl-D-aspartate (NMDA) Adaptive Mechanisms Upregulation of D synthesis Downregulation of synaptic D reuptake Chen JJ et al. Chapter 68. Parkinson's Disease. In: Talbert RL et al, eds. Pharmacotherapy: A Pathophysiologic 5
6 Clinical Presentation Hallmark motor signs Resting tremor Rigidity Bradykinesia Chen JJ et al. Chapter 68. Parkinson's Disease. In: Talbert RL, et al., eds. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York: McGraw-Hill; Other signs/symptoms Posture/Movement: Postural instability, difficulty rising from seated position, diminished arm swing during ambulation, flexed posture, freezing at initiation of movement Decreased manual dexterity Voice/Throat: Dysarthria, hypophonia, dysphagia Hypomimia Micrographia Constipation, bladder dysfunction Mental status changes Common Causes of Secondary PD Antiemetics: metoclopramide, prochlorperazine Antipsychotics: haloperidol, risperidone, olanzapine Other agents: methyldopa 6
7 Drugs Used to Treat PD Any Stage of Disease MAO-B Inhibitors Dopamine Agonists Levodopa/Carbidopa Anticholinergics Amantadine Advanced Stage COMT Inhibitors Apomorphine 7
8 MAO-B Inhibitors Mechanism of Action: irreversible inhibition of D degradation Slow decline of motor function Questionable disease modification Drug Interactions: Antidepressants, St. John s Wort Sympathomimetics Dextromethorphan Meperidine, tramadol, methadone Tyramine-containing foods Well tolerated as monotherapy (arthralgia, dyspepsia, depression, flu syndrome) AZILECT (rasagiline) package insert. Revised August MAO-B Inhibitors: Preparations Rasagiline AZILECT mg po daily Avoid high tyramine content foods (eg, aged cheeses) Metabolized by CYP1A2: ciprofloxacin AZILECT (rasagiline) package insert. August ZELAPAR (selegiline ODT) package insert. February Selegiline tablets (Mylan) package insert. November EMSAM (selegiline transdermal) package insert. August Selegiline Tablets: 5 mg po at breakfast and lunch Avoid all tyramine-containing foods ODT: ZELAPAR 1.25 mg daily; escalate to 2.5 mg daily after 6 weeks Faster onset than tablets Avoid all tyramine-containing foods Patch (EMSAM) Not approved for PD 8
9 Amantadine Mechanism of Action: D agonist and NMDA antagonist 300 mg/day, in divided doses Renally eliminated Adverse Effects: dizziness, confusion, dry mouth, hallucinations, livedo reticularis Anticholinergic Agents Mechanism of Action: Common Adverse Effects ACh Dopamine Included in 2012 Update to the Beers Criteria Useful for rigidity and tremor Preparations: Benztropine Trihexyphenidyl J Am Geriatr Soc. 2012;60:
10 Dopamine Agonists More consistent effects than levodopa Nonergot vs ergot-derived Mechanism of action: non-ergot agonist with full intrinsic activity at D2 receptor Significant adverse effects: nausea, sleep attacks, orthostatic hypotension, lack of impulse control, hallucinations, withdrawal, melanoma Lower risk for dyskinesias Ann Neurol. February 2011;69: MIRAPEX (pramipexole) package insert. Revised September REQUIP (ropinirole) package insert. Revised May Dopamine Agonists: Preparations Oral Agents (also extended release) Pramipexole (MIRAPEX ) mg po TID titrated weekly to 1.5 mg po TID Renally eliminated Ropinirole (REQUIP ) 0.25 mg po TID titrated weekly to 1 mg po TID Metabolized by CYP1A2 Ciprofloxacin Estrogens Transdermal Product Rotigotine (NEUPRO ) 2 mg patch daily titrated weekly by 2 mg up to 8 mg Caution in patients with sulfite allergy Dose-dependent application site reactions Hypertension, tachycardia, weight gain, and fluid retention MIRAPEX (pramipexole) package insert. Revised September REQUIP (ropinirole) package insert. Revised May NEUPRO (rotigotine transdermal) package insert. Revised April 2o12 10
11 Levodopa/Carbidopa Mechanism of action: Levodopa: precursor of dopamine Carbidopa: peripheral L-amino acid decarboxylase inhibitor Maximum required daily dose: mg Effective half life: 1.5 hours Common adverse effects: orthostasis, dyskinesias, motor fluctuations, psychosis Formulations: Immediate release Controlled release Orally disintegrating COMT Inhibitors Mechanism of action: in combination with carbidopa, reduce peripheral conversion of levodopa Extends levodopa half life to 2 to 2.5 hours Drug interactions: epinephrine, norepinephrine, dobutamine, methyldopa Adverse effects: diarrhea, colitis COMTAN (entacapone) package insert. Revised April
12 COMT Inhibitor Formulations Entacapone COMTAN 200 mg with each levodopa/carbidopa dose STALEVO Carbidopa/levodopa/ entacapone combination product Tolcapone TASMAR 100 mg po TID Risk of liver injury must monitor AST/ALT Patients must show clinical benefit within 3 weeks COMTAN (entacapone) package insert. Revised April STALEVO (carbidopa/levodopa/entacapone) package insert. Revised April TASMAR (tolcapone) package insert. Revised June Apomorphine (APOKYN ) Parenteral nonergot D agonist On response within 20 minutes of injection; duration ~100 minutes 2-6 mg/injection; usually 0.06 mg/kg (pen is labeled in ml) Complicated test dose and titration procedure required Rotate injection site Adverse effects: nausea/vomiting; dizziness, hallucinations, ISR, orthostasis, somnolence, hypotension, QTc prolongation Drug Interactions: 5HT3 antagonists; QTc-prolonging drugs, antihypertensives APOKYN (apomorphine) package insert. Revised February
13 Suggested Treatment Algorithm Initial treatment: MAO-B Inhibitor Augmenting treatment: Tremor: Amantadine If <65 y, consider anticholinergics Bradykinesia, rigidity, tremor: Amantadine Dopamine replacement: dopamine agonist, carbidopa/levodopa Chen JJ, et al. Chapter 68. Parkinson's Disease. In: Talbert RL, et al., eds. Pharmacotherapy: A Pathophysiologic 13
14 Beginning Treatment With MAO-B Inhibitor: The TEMPO Trial Patients: Untreated, early PD patients Anticholinergics allowed Interventions: Rasagiline 1 mg or 2 mg or placebo Outcomes: Both agents had better UPDRS scores than placebo No difference in time to need more therapy between groups Overall, drug was well tolerated Arch Neurol. 2002;59: Beginning Treatment With MAO-B Inhibitor: The ADAGIO Trial Patients: Untreated, early PD patients Interventions: Phase 1: Rasagiline 1 mg or 2 mg or 1 mg or 2 mg placebo Phase 2: active group continue treatment; placebo switch to active treatment Outcomes: Patients receiving 1 mg had slower rate of worsening than placebo patients Early start 1 mg group had less worsening in UPDRS than delayed start group 2 mg rasagiline dose demonstrated negative results No tyramine or serotonin reactions noted N Engl J Med. 2009;361:
15 Choosing Between Dopamine Replacements Dopamine Agonists Levodopa/Carbidopa Dyskinesias Reduced 10% per year Common adverse effects Orthostasis, nausea Orthostasis Half life Long Short Best tolerated by Young patients Older patients Other benefits Reduced free radical formation? Neuropsychopharmacology. 2012;37: Ann Neurol 2011;69: Early Exposure to Levodopa: The ELLDOPA trial Patients: Untreated, early-stage PD Interventions: Placebo L/C 50/12.5 TID L/C 100/25 TID L/C 200/50 TID 40-week treatment, 3 day step down, 2-week assessment Outcomes: Dose-response seen from weeks 9 to 40 Deterioration seen in all treatment groups at week 42, but not to same level as placebo AEs seen in 600 mg group: Dyskinesia Nausea Infection Hypertonia Headache N Engl J Med. 2004;351:
16 Motor Fluctuations End-of-Dose Wearing Off Delayed-on/No-on Freezing Dyskinesia Off-Period 16
17 End-of-Dose Wearing Off Increase frequency of levodopa administration Add additional agents: COMT Inhibitor MAO-B inhibitor Apomorphine D agonist Controlled release formulations Sipping levodopa/carbidopa suspension Delayed-On or No-On Causes Delayed gastric emptying Decreased absorption Treatments Ensure empty stomach Chew/crush tablet with glass of water Dosage formulation ODTs Avoid controlled-release Apomorphine rescue Chen JJ, et al. Chapter 68. Parkinson's Disease. In: Talbert RL, et al., eds. Pharmacotherapy: A Pathophysiologic 17
18 Freezing Frequently related to anxiety PT is mainstay of therapy Pharmacologic treatment Increase levodopa/carbidopa dose Add D agonist or MAO-B inhibitor Dyskinesias Peak striatal dopamine levels Treatments Change to IR products Smaller, more frequent levodopa doses Reduce dose of other agents Amantadine Clozapine(?) Ann Neurol 2-11;69:
19 Off-Period Dystonia Frequently occurs in early morning hours Treatments: Long-acting dopamine agonist Sustained-release carbidopa/levodopa Baclofen Local injection of botulinum toxin Adherence Issues Adherent patients are 67% less likely to develop PD complications Hospitalizations Office visits Ancillary care visits Cost of nonadherence: ~$5000/year AND Only 1/3 of patients are adherent 80% of the time Mov Disord. 2010;25: Mov Disord. 2008;23:
20 How Can the Pharmacist Help? Coaching and encouragement at refills Refill reminders Auto-fills Pill boxes Alternate routes/frequencies Referral to special programs Home care Transitional care 20
21 Novel Delivery Methods Continuous subcutaneous apomorphine Efficacy as monotherapy 64% reduction in dyskinesia Maximal improvement at 12 months Skin inflammation, cognitive/psychiatric disorders Intraintestinal levodopa/carbidopa Micronized in methylcellulose gel Continuous infusion with boluses prn Long-term stable responses with decreases in off time 94.7% of patients with dyskinesias improved Ann Neurol. 2011;69: Adenosine A 2A Antagonists A 2A receptors found along with D2 receptors in striatum A 2A receptors mediate glutamate and GABA activity Preladenant: modest effects Phase II trials: SYN 115 BII 014 Neuropsychopharmacology. Reviews February 2012;37:
22 Glutamate Receptor-Related Compounds Glutamate is overexpressed in PD NMDA receptor is 1 subfamily of glutamate receptors Amantadine is currently the only effective drug with anti-nmda activity Memantine, riluzole, and remacemide are not beneficial Neuropsychopharmacology Reviews. February 2012;37: Other Compounds Under Development Methylphenidate: low doses may be useful for gait disturbances Fipamezole: alpha 2c adrenoceptor antagonist Phase IIb trials demonstrate efficacy for dyskinesia Neuropsychopharmacology Reviews February 2012;37:
23 Thank You! 23
Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationCardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.
Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor
More informationMotor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,
More informationparts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to
parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug
More informationWhat s new for diagnosing and treating Parkinson s Disease?
What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology
More informationMedications used to treat Parkinson s disease
Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John
More informationTreatment of Parkinson s Disease: Present and Future
Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing
More informationParkinson s Disease Medications: Professionals Edition
Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu
More informationDrug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationParkinson s Disease Current Treatment Options
Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority
More informationPD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.
PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N. To hear the session live on: Tuesday, April 17, 2012 at 1:00 PM ET. DIAL: 1 (888) 272-8710 and
More information10th Medicine Review Course st July Prakash Kumar
10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS
More informationParkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015
Parkinson s Disease Update Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015 Parkinson s Disease Progressive, chronic, neurodegenerative disease Slow,
More informationBest Medical Treatments for Parkinson s disease
Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells
More information9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations
Parkinson s Disease Update Clinical and Operational Considerations Dana Saffel, PharmD, BCGP, CPh, FASCP President, CEO PharmaCare Strategies, Inc. September 2018 Objectives Describe epidemiology and pathophysiology
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationParkinson s Disease. Sirilak yimcharoen
Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically
More informationParkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.
Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationCommunicating About OFF Episodes With Your Doctor
Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March
More informationDrugs used in Parkinsonism
Drugs used in Parkinsonism قادة فريق علم األدوية : لي التميمي & عبدالرحمن ذكري الشكر موصول ألعضاء الفريق املتميزين : جومانة القحطاني ندى الصومالي روان سعد القحطاني pharma436@outlook.com @pharma436 Your
More informationKey Concepts and Issues in Parkinson s Disease in 2016
Key Concepts and Issues in Parkinson s Disease in 2016 Michael Rezak, M.D., Ph.D. Section Chief, Neurosciences Institute Director, Movement Disorders and Neurodegenerative Diseases Center Northwestern
More informationDrugs for Parkinson s Disease
This Clinical Resource gives subscribers additional insight related to the Recommendations published in July 2017 ~ Resource #330705 Drugs for Parkinson s Disease Parkinson s disease is characterized by
More informationOptimizing Clinical Communication in Parkinson s Disease:
Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of
More informationPARKINSON S MEDICATION
PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development
More informationFaculty. Joseph Friedman, MD
Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationEvaluation and Management of Parkinson s Disease in the Older Patient
Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of
More informationObjectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.
Objectives Emerging Treatments in Parkinson s s Disease 1) Describe recent developments in the therapies for Parkinson s Disease Jeff Kraakevik MD Assistant Professor OHSU/Portland VAMC Parkinson s Center
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationXADAGO (safinamide) oral tablet
XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationParkinson s Disease. Gillian Sare
Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second
More informationPARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease
5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater
More information475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)
475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called
More informationCE on SUNDAY Newark, NJ October 18, 2009
CE on SUNDAY Newark, NJ October 18, 2009 Date: Sunday, October 18, 2009 Time: 10:30 AM 11:45 AM Location: Sheraton Newark Airport Hotel Title: Speaker(s): Treating Parkinson s Disease: A Pharmacist s Overview
More informationProgram Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York
Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone
More informationClinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationPD: Key Treatment Considerations
PD: Key Treatment Considerations 2018 Management of Neurologic and Neurosurgical Disorders in Daily Practice Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 11/27/2018 1 Outline Treatment
More informationAdvanced Therapies for Motor Symptoms in PD. Matthew Boyce MD
Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationPL CE LIVE July 2015 Forum
July 2015 PL CE LIVE Rachel Maynard, PharmD Associate Editor Pharmacist s Letter/Pharmacy Technician s Letter CE Information Pharmacist's Letter / Therapeutic Research Center is accredited by the Accreditation
More informationThe Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates
The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates Editor: Marsha K. Millonig, MBA, RPh President/CEO Catalyst Enterprises,
More informationMedication Management & Strategies When the levodopa honeymoon is over
Medication Management & Strategies When the levodopa honeymoon is over Eric J Pappert, MD Parkinson s Disease & Movement Disorders Center Neurology Associates Medication Options in Parkinson s Carbidopa/Levodopa
More informationAnticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:
More informationParkinson s Pharmacology
PHPP 517 (IT-III) Fall 2011 JACOBS Wed 10/12 8:00 8:50 AM 1 Learning objectives 1. Describe the direct and indirect pathways of the extrapyramidal system and its modulation by ACh and DA. 2. Contrast the
More informationCommonly encountered medications and their side effects - what the generalist needs to know
Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and
More information8/28/2017. Behind the Scenes of Parkinson s Disease
BEHIND THE SCENCES IN Parkinson s Disease Behind the Scenes of Parkinson s Disease Anna Marie Wellins DNP, ANP C Objectives Describe prevalence of Parkinson's disease (PD) Describe the hallmark pathologic
More informationUpdate to Product Monograph
Dear Healthcare Professional, July 2012 Please be informed that the AZILECT Product Monograph has been updated. The monograph format is in line with the new Product Monograph template Updated Contraindications
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationParkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s
Parkinson s Disease Update Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s What is a movement disorder? Neurological disorders that affect ability to move by causing
More informationScottish Medicines Consortium
Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium
More informationDrugs Affecting the Central Nervous System
Asst Prof Inam S Arif isamalhaj@yahoo.com Drugs Affecting the Central Nervous System Ass Efferent neurons in ANS Neurodegenerative Diseases Parkinson s Disease Multiple Sclerosis Alzheimer s Disease
More informationPrior Authorization with Quantity Limit Program Summary
Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.
More informationParkinson s Disease: the ABC s of PD Drug Therapy
Parkinson s Disease: the ABC s of PD Drug Therapy Kimberly Mulcahy, PharmD, BCPS Clinical Pharmacist Buffalo Psychiatric Center NYSOMH Adjunct Faculty University at Buffalo SoPPS Disclosure No financial
More informationUpdate in the Management of Parkinson s Disease
Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &
More informationWhat is Parkinson s Disease?
2018 Update in Parkinson s Disease: Treatments and Future Plans Arita McCoy, MSN, CRNP Johns Hopkins Parkinson s Disease and Movement Disorder Center A National Parkinson Foundation Center of Excellence
More informationPARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada
PARKINSON S PRIMER Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada COPYRIGHT 2017 BY SEA COURSES INC. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationParkinson s Disease Update
Parkinson s Disease Update Elise Anderson MD Providence Center for Parkinson s Disease October 26, 2017 11/6/2017 1 Disclosures GE Speaker, DaTSCAN 11/6/2017 2 Outline PD diagnosis Motor and nonmotor symptoms
More informationWhat is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease
FPIN's Clinical Inquiries Treatment of Early Parkinson's Disease Clinical Question What is the best medical therapy for early Parkinson's disease? Evidence-Based Answer Treatment of early Parkinson's disease
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationDrug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)
Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl
More informationParkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center
Parkinsons Disease update Sindhu R Srivatsal MD MPH Virginia Mason Medical Center PARKINSONISM Vs PARKINSON S Parkinsonism Bradykinesia: slowness of movements (essential feature) PLUS one of Tremor: resting
More informationParkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder
Prevalence Parkinson s Disease Mark S. Baron, M.D. Associate Professor of Neurology Movement Disorders Section VCU School of Medicine Common disorder Approaching 1% by 65 yrs of age, 2% by 80 yrs of age
More informationParkinson s Disease and Treatment Options for the Younger Adult
Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had Tremor of her right hand
More informationParkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD
Parkinson s Disease: initial diagnosis, initial treatment & non-motor features J. Timothy Greenamyre, MD, PhD Involuntary tremulous motion, with lessened muscular power, in parts not in action and even
More informationParkinson s Disease and Treatment Options for the Younger Adult
The Way CME Should Be Parkinson s Disease and Treatment Options for the Younger Adult David E. Riley, M.D. Chair, Medical Education InMotion April 22, 2016 Case Presentation - 1 A 57-year-old woman had
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationMargo J Nell Dept Pharmacology
Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce
More informationWHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019
WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019 YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Addressing Motor and Non-Motor Symptoms The Changing Landscape Wednesday, March 8, 2017 Welcome and Introductions Stephanie Paul Vice President Development and Marketing
More informationFOR PARKINSON S DISEASE XADAGO NEXT?
FOR PARKINSON S DISEASE XADAGO can increase your daily on time without troublesome dyskinesia 1 Please see the complete Important Safety Information on pages 12-13 and the accompanying full Prescribing
More informationACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM
ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD
More informationPARKINS ON CENTER. Parkinson s Disease: Diagnosis and Management. Learning Objectives: Recognition of PD OHSU. Disclosure Information
OHSU PARKINS ON CENTER Parkinson s Disease: Diagnosis and Management for Every MD Disclosure Information Grants/Research Support: National Parkinson Foundation, NIH, Michael J. Fox Foundation Consultant:
More informationParkinson s Disease. Graham A. Glass, MD. Assistant Professor of Neurology University of California San Francisco
Parkinson s Disease Graham A. Glass, MD Assistant Professor of Neurology University of California San Francisco San Francisco VA Medical Center Parkinson s Disease Research, Education and Clinical Center
More informationParkinson's Disease. Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology
Parkinson's Disease Robert L. Copeland, Ph.D. Howard University College of Medicine Department of Pharmacology 18 February 2002 Parkinson Disease Neurological disease affecting over four million patients
More informationNew Medicines Committee Briefing July 2011
New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole
More informationEvaluation of Parkinson s Patients and Primary Care Providers
Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,
More informationUpdate on the Treatment of Parkinson s Disease. Neurotherapeutics for Rehab Professionals November 6 th, 2015
Brent Bluett, DO Dr. Brent Bluett completed medical school at Touro Unviersity Nevada College of Osteopathic Medicine, neurology residency at the University of Texas Southwestern at Austin, and a Movement
More informationWith Time, The Pathology of PD Spreads Throughout the Brain
With Time, The Pathology of PD Spreads Throughout the Brain Braak s staging of Parkinson s disease pathology dm co sn mc hc fc 1 Hubert H. Fernandez, MD, FAAN Professor of Medicine (Neurology) Cleveland
More informationClinical Guideline for the management of inpatients with Parkinson s disease
Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,
More informationRotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research
Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research Synthetic DRUG PROFILE Introduction Parkinson s disease (PD) is a neurodegenerative disorder
More informationParkinson's Disease and how you can make a difference with medication
Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy
More informationAlison Charleston 1 st September 2016
Alison Charleston 1 st September 2016 Clinical features of Parkinson s disease Differential diagnosis Management of the motor features Non-motor and neuropsychiatric aspects 100-200 per 100,000 prevalence
More information2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).
Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,
More informationMANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW
MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:
More informationNovel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK
Novel approaches to the pharmacological treatment of Parkinson s disease Peter Jenner King s College UK Disclosures and Disclaimers Speakers fees and consultancy fees have been received from Britannia
More informationTRANSPARENCY COMMITTEE OPINION. 18 March 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379
More informationLiterature Scan: Anti-Parkinson s Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationVolume 28 (3) Chairman, Medical Review Laird Birmingham, M.D., M.H.Sc., F.R.C.P.(C) Department of Medicine St. Paul s Hospital RASAGILINE
Volume 28 (3) 2008 Editor: Barbara Cadario, B.Sc.(Hon), B.Sc.Phm., M.Sc. Contents Rasagiline - B Cadario Chairman, Medical Review Laird Birmingham, M.D., M.H.Sc., F.R.C.P.(C) Department of Medicine St.
More informationPUBLIC SUMMARY OFRISK MANAGEMENT PLAN
RASAGILINE ORION 1 MG TABLETS PUBLIC SUMMARY OFRISK MANAGEMENT PLAN DATE: 08-07-2015, VERSION 1.1 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Parkinson s disease (PD) is
More informationParkinson s Disease. Medications
Parkinson s Disease Medications By David Houghton, MD, MPH, Howard Hurtig, MD, and Sharon Metz, RN, MPH, with guest authors Monique Giroux, MD, Giselle Petzinger, MD, Beth Fisher, PT, PhD, Lauren Hawthorne,
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationParkinson s Disease and Its Treatment
Parkinson s Disease and Its Treatment By H. David Bergman, Ph.D. Dean, Southwestern Oklahoma State University, College of Pharmacy Goals and Objectives Goals: To provide the pharmacist with information
More information